ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01708629
Recruitment Status : Terminated (Sponsor decision)
First Posted : October 17, 2012
Last Update Posted : December 22, 2015
Sponsor:
Information provided by (Responsible Party):
Amgen

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : August 2014
  Actual Study Completion Date : October 2015
  Certification/Extension First Submitted : April 14, 2015

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 November 8, 2016 January 6, 2017
2 February 8, 2017 March 28, 2017
3 April 7, 2017 May 18, 2017
4 July 31, 2017 August 30, 2017
5 December 8, 2017 January 8, 2018